Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Profit After Tax (2016 - 2026)

Amphastar Pharmaceuticals has reported Profit After Tax over the past 13 years, most recently at $24.4 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 35.65% year-over-year to $24.4 million; the TTM value through Dec 2025 reached $98.1 million, down 38.51%, while the annual FY2025 figure was $98.1 million, 38.51% down from the prior year.
  • Profit After Tax for Q4 2025 was $24.4 million at Amphastar Pharmaceuticals, up from $17.3 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $49.2 million in Q3 2023 and troughed at $5.0 million in Q1 2021.
  • A 5-year average of $27.4 million and a median of $26.1 million in 2023 define the central range for Profit After Tax.
  • Biggest five-year swings in Profit After Tax: surged 4145.31% in 2021 and later tumbled 57.09% in 2025.
  • Year by year, Profit After Tax stood at $19.8 million in 2021, then skyrocketed by 71.62% to $33.9 million in 2022, then grew by 6.65% to $36.2 million in 2023, then increased by 4.97% to $38.0 million in 2024, then plummeted by 35.65% to $24.4 million in 2025.
  • Business Quant data shows Profit After Tax for AMPH at $24.4 million in Q4 2025, $17.3 million in Q3 2025, and $31.0 million in Q2 2025.